Review Article
GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes
Pickart L, Margolina A. Cosmetics. 2018
Compare
GHK-Cu vs Thymosin Alpha-1
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
GHK-Cu
120 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Mood
226
Recovery
226
Energy
1
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
222
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 2–3 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
1
0.025–0.05 mg
16
0.2–0.4 mg
4
0.6–1 mg
1
1–2 mg
71
2–3 mg
87
3–5 mg
43
5+ mg
5
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 89% said they felt similar to their last entry, 11% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 46 days · Based on 45 repeat reporters
Thymosin Alpha-1
7 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
7
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Inflammation
1
Self-reported dose per injection
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.4–2 mg
0.4–0.6 mg
4
1–2 mg
3
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Sources (12)
Published sources linked on the GHK-Cu and Thymosin Alpha-1 wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
GHK-Cu in wound healing and tissue regeneration
Pickart L. J Biomater Sci Polym Ed. 2008
- Wiki study page →Source
PubMed
GHK peptide as a natural modulator of multiple cellular pathways
Pickart L, Margolina A. Biomed Res Int. 2014
- Wiki study page →Source
ClinicalTrials.gov
GHK-Cu copper peptide studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
Pickart L, Vasquez-Soltero JM, Margolina A. BioMed research international. 2015
- Wiki study page →Source
PubMed
Biomimetic Hydrogel Scaffolds with Copper Peptide-Functionalized RADA16 Nanofiber Improve Wound Healing in Diabetes
Yang X, Zhang Y, Huang C, et al. Macromolecular bioscience. 2022
- Wiki study page →Source
PubMed
Thymosin alpha 1: A comprehensive review of the literature
Romani L, Moretti S, Fallarino F, et al. Expert Opin Biol Ther. 2020
- Wiki study page →Source
PubMed
Thymosin alpha 1: past clinical experience and future promise
Tuthill C, Rios I, McBeath R. Ann N Y Acad Sci. 2010
- Wiki study page →Source
PubMed
Thymosin alpha 1 as adjuvant therapy for melanoma and other cancers
Garaci E, Pica F, Serafino A, et al. Ann N Y Acad Sci. 2014
- Wiki study page →Source
ClinicalTrials.gov
Thymosin alpha-1 studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach
Naylor PH, Mutchnick MG. Journal of viral hepatitis. 2018
- Wiki study page →Source
PubMed
Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection
Al-Mahtab M, Bazinet M, Vaillant A. PloS one. 2016